T-cell membrane-anchored tumor-targeted IL-12-modified tumor infiltrating lymphocytes

A preparation of tumor infiltrating lymphocytes (TILs) engineered to express membrane-bound interleukin-12 (mbIL-12), with potential immunomodulating and antineoplastic activities. Upon infusion of the T-cell membrane-anchored tumor-targeted IL-12-modified TILs, the cells specifically recognize and kill the tumor cells. IL-12 expression activates the immune system by promoting the secretion of interferon-gamma (IFNg), activating natural killer cells (NKs), and inducing cytotoxic T-lymphocyte (CTL) responses, further killing tumor cells.